PARABILIS MEDICINES PRESENTS UPDATED PHASE 1/2 DATA FOR ZOLUCATETIDE DEMONSTRATING COMPELLING EFFICACY AND FAVORABLE SAFETY AND TOLERABILITY PROFILE IN PATIENTS WITH DESMOID TUMORS

Reuters · 2d ago

Please log in to view news